News Sentiment

HUMA sentiment intelligence

Humacyte Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 53 Balanced news tone 62 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 0.69 Week of 10 Jul 2026
Weighted tone 53/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

76/100 classification confidence.

Company focus 53

directly relevant articles

Source quality 1

high-authority source matches

Trend context Trend inactive

-2.3% over one week, -34.2% over four weeks, trend inactive, and below fair value.

Latest direct headline Positive

Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know

Market Reaction

Balanced read

60/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 76/100 classification
One-week reaction -2.3% Price reacting lower
Trend fit Trend inactive -34.2% over four weeks
Fair value -77.4% Below fair value
Value support

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 14
Neutral 39
Negative 9

Relevance

Why the article matched

Direct first
Direct company coverage 53
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 12
Stock Titan 12
TradingView 7
Investing.com 5
simplywall.st 5
TradingKey 4
The Manila Times 2
StockStory 1

Event Lens

What the news is about

Classified themes
Market update 28
Earnings 25
Analyst action 4
Deals and strategy 3
Capital return 1
Balance sheet 1

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 1-30 of 62
Market source Direct company coverage

Humacyte, Inc. (HUMA) Beats Stock Market Upswing: What Investors Need to Know

Humacyte, Inc. (HUMA) saw its stock price increase by 2.31% in a recent trading session, outperforming the S&P 500, Dow, and Nasdaq. The company is projected to report a significant increase in EPS and revenue in its upcoming financial release. Despite a recent downward shift in

Tone
Positive 62/100
Event
Earnings
Published
15 Jul 2026 06:12
Source
Market source
Investing.com Direct company coverage

Humacyte appoints two nephrologists as commercial advisors

Humacyte, Inc. (NASDAQ:HUMA) has appointed Dr. Robert J. Kossmann and Dr. Prabir Roy-Chaudhury as commercial advisors to assist with the planned commercialization of its acellular tissue engineered vessel (ATEV) for hemodialysis access. This move follows positive results from its

Tone
Positive 70/100
Event
Earnings
Published
14 Jul 2026 15:11
Source
Investing.com
The Manila Times Direct company coverage

Humacyte Appoints Key Nephrologists as Advisors to Prepare for Planned Commercialization of the ATEV in Dialysis Access

Humacyte has announced the appointment of Dr. Robert J. Kossmann and Dr. Prabir Roy-Chaudhury as advisors to assist with the planned commercialization of their acellular tissue engineered vessel (ATEV) for hemodialysis access. These leading nephrologists will contribute to health

Tone
Positive 73/100
Event
Market update
Published
14 Jul 2026 12:11
Source
The Manila Times
Stock Titan Direct company coverage

Two Kidney Specialists Join Humacyte Ahead of Planned Dialysis Access

Humacyte (Nasdaq: HUMA) has appointed leading nephrologists Dr. Robert J. Kossmann and Dr. Prabir Roy-Chaudhury as advisors to support the commercialization of its acellular tissue engineered vessel (ATEV) for hemodialysis access. These appointments follow positive Phase 3 study

Tone
Positive 63/100
Event
Market update
Published
14 Jul 2026 12:11
Source
Stock Titan
Investing.com Nigeria Direct company coverage

Form 13D/A HUMACYTE For: 13 July By Investing.com

This article provides details about a Form 13D/A filing for HUMACYTE on July 13. It includes the stock symbol HUMA and details a slight price increase of 2.10%. The content is brief, primarily serving as an announcement of the SEC filing.

Tone
Neutral 50/100
Event
Market update
Published
13 Jul 2026 22:28
Source
Investing.com Nigeria
Stock Titan Direct company coverage

Fresenius to sell 5M Humacyte (HUMA) shares under Rule 10b5-1 plan

Fresenius Medical Care Holdings, Inc. and Fresenius Medical Care AG plan to reduce their stake in Humacyte, Inc. by selling up to 5,000,000 common shares through a Rule 10b5-1 trading plan. This move is part of FME AG's "FME Reignite" strategy, aiming to lower their beneficial ow

Tone
Negative 38/100
Event
Deals and strategy
Published
13 Jul 2026 21:42
Source
Stock Titan
Finviz Direct company coverage

HUMA - Humacyte Inc Options

This article provides a detailed financial overview of Humacyte Inc. (HUMA), including its last close price, market capitalization, income, sales, and various financial ratios. It also lists key performance indicators such as EPS growth, insider and institutional ownership, profi

Tone
Neutral 50/100
Event
Earnings
Published
04 Jul 2026 15:09
Source
Finviz
TradingView Direct company coverage

Enterprise value to revenue forward of Humacyte, Inc. – NASDAQ:HUMAW

This article provides a brief financial overview for Humacyte, Inc. (NASDAQ: HUMAW), focusing on its enterprise value to revenue forward metric. The content highlights the company's stock market information and indicates a focus on financial data without elaborating on specific f

Tone
Neutral 50/100
Event
Earnings
Published
01 Jul 2026 17:39
Source
TradingView
TradingView Direct company coverage

Humacyte, Inc. Warrant 2021-27.08.26 on Humacyte Financial Disclosures & SEC Filings

This page provides access to Humacyte, Inc.'s SEC filings and other important company documents, including earnings reports, annual and quarterly reports, corporate presentations, and event transcripts. The documents span from 2026 back to 2023, offering detailed insights into th

Tone
Neutral 50/100
Event
Earnings
Published
01 Jul 2026 09:11
Source
TradingView
Yahoo! Finance Canada Direct company coverage

Humacyte, Inc. (HUMA) Stock Sinks As Market Gains: Here's Why

Humacyte Inc.'s stock (HUMA) dropped by 2.32% on the last trading day, underperforming the broader market gains. Over the past month, the stock has fallen 44.9%. Analysts project positive earnings and revenue growth for the upcoming quarter, but the company currently holds a Zack

Tone
Negative 30/100
Event
Earnings
Published
30 Jun 2026 22:00
Source
Yahoo! Finance Canada
Global Legal Chronicle Direct company coverage

Humacyte Announces $50 Million Public Offering of Common Stock

Humacyte Inc. (Nasdaq: HUMA), a commercial-stage biotechnology platform company, has announced a $50 million public offering of common stock. Paul Hastings LLP advised Barclays, BTIG, and Titan Partners on the offering, while Covington & Burling LLP advised Humacyte Inc. Further

Tone
Positive 66/100
Event
Market update
Published
30 Jun 2026 00:11
Source
Global Legal Chronicle
TradingView Direct company coverage

Humacyte, Inc. Actuals & Estimates (NASDAQ:HUMA)

This article provides an overview of Humacyte, Inc. (NASDAQ:HUMA) stock, including its current price, historical performance, analyst forecasts, and financial data. It covers key metrics like market capitalization, earnings, revenue, and EBITDA, along with information on future e

Tone
Negative 40/100
Event
Earnings
Published
28 Jun 2026 05:09
Source
TradingView
TradingView Direct company coverage

Price to earnings forward of Humacyte, Inc. – NASDAQ:HUMA

This page from TradingView provides a financial overview for Humacyte, Inc. (NASDAQ: HUMA), specifically focusing on its price-to-earnings forward metric. The content highlights the company's stock market information and indicates no recent trades, suggesting the market was close

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 14:41
Source
TradingView
Market source Direct company coverage

Humacyte (HUMA) Stock Fair Value Falls As Split Analyst Views Follow V012 Data

Humacyte's (HUMA) fair value estimate has significantly decreased from US$7.86 to US$2.05 following the V012 data release, reflecting split analyst views. While some analysts are bullish on the acellular vessel opportunity, others have trimmed expectations due to increased cautio

Tone
Negative 40/100
Event
Analyst action
Published
27 Jun 2026 10:06
Source
Market source
TradingView Direct company coverage

Price to earnings forward of Humacyte, Inc. – BOATS:HUMA

This article provides financial information for Humacyte, Inc. (HUMA) on the TradingView platform, specifically focusing on its Price to Earnings Forward metric. The content highlights the company's stock symbol on the Blue Ocean Alternative Trade System (BOATS). The brief articl

Tone
Neutral 50/100
Event
Earnings
Published
27 Jun 2026 05:10
Source
TradingView
TradingView Direct company coverage

Enterprise value to revenue forward of Humacyte, Inc. – BOATS:HUMA

The article provides the enterprise value to revenue forward for Humacyte, Inc. (HUMA) on the Blue Ocean Alternative Trade System (BOATS:HUMA). It highlights that the market was closed at the time of publication, with no trades reported. The information is presented within the co

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 08:41
Source
TradingView
Stock Titan Direct company coverage

Davidson Kempner reports 4.74% stake in Humacyte (NASDAQ: HUMA)

Davidson Kempner-affiliated entities have reported a 4.74% stake in Humacyte (NASDAQ: HUMA) through a Schedule 13G filing. This amounts to 12,787,073 shares, calculated based on 269,638,156 shares outstanding. Anthony A. Yoseloff is identified as responsible for the voting and in

Tone
Neutral 50/100
Event
Deals and strategy
Published
22 Jun 2026 21:40
Source
Stock Titan
Investing.com Canada Direct company coverage

Form 13G Humacyte For: 22 June By Investing.com

This article reports on a Form 13G filing for Humacyte (HUMA) on June 22. It is a brief announcement from Investing.com and includes financial data and various market indices, but no specific details about the filing itself. The article also contains a list of popular news and ma

Tone
Neutral 50/100
Event
Market update
Published
22 Jun 2026 21:40
Source
Investing.com Canada
MSN Direct company coverage

Humacyte, Inc. (HUMA) dips more than broader market: What you should know

This article from MSN discusses that Humacyte, Inc. (HUMA) experienced a stock dip that was more significant than the broader market's decline. It suggests investors might want to investigate the reasons behind this underperformance.

Tone
Negative 30/100
Event
Market update
Published
18 Jun 2026 17:39
Source
MSN
TradingKey Direct company coverage

Humacyte Inc (HUMA) Institutional Confidence

Humacyte Inc (HUMA) has an institutional shareholding score of 3.00, placing it 193rd out of 388 in the Biotechnology & Medical Research industry. The institutional shareholding proportion increased by 29.83% quarter-over-quarter to 32.47%. Fresenius SE & Co KGaA is the largest i

Tone
Neutral 50/100
Event
Market update
Published
18 Jun 2026 05:39
Source
TradingKey
TradingKey Direct company coverage

Humacyte Inc (HUMA) Earnings Forecast: Future EPS & Revenue Growth Estimates

Humacyte Inc (HUMA) has an earnings forecast score of 8.00, placing it 163rd in its industry. Analysts have set an average price target of $3.50 for HUMA, with individual targets ranging from $3.00 to $25.00. The company's expected revenue for the next quarter is $1.12 million, a

Tone
Positive 67/100
Event
Earnings
Published
18 Jun 2026 03:39
Source
TradingKey
TradingKey Direct company coverage

Humacyte Inc (HUMA) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution

This article provides a revenue breakdown for Humacyte Inc (HUMA), focusing on its business segments, regional revenue, and profit contribution. It notes that relevant data for several fiscal quarters of FY2025 and FY2022 has not yet been disclosed by the company. The only specif

Tone
Neutral 50/100
Event
Earnings
Published
17 Jun 2026 17:10
Source
TradingKey
Quartr Direct company coverage

Humacyte (HUMA) Barclays 28th Annual Global Healthcare Conference Summary

Humacyte (HUMA) presented at the Barclays 28th Annual Global Healthcare Conference, highlighting the commercial progress of its vascular product, which has seen improved adoption after a price adjustment and increased focus on education. The company detailed positive clinical tri

Tone
Positive 71/100
Event
Market update
Published
16 Jun 2026 08:11
Source
Quartr